In vitro effects of growth hormone (GH) and insulin-like growth factor I and II (IGF-I and -II) on chromosome fragility and p53 protein expression in human lymphocytes

European Journal of Clinical Investigation

Volumn 28, Issue 1, 1998, Pages 41-47

  Cianfarani, S ^a   Tedeschi, B ^a   Germani, D ^a   Prete, S P ^a   Rossi, P ^a   Vernole, P ^a   Caporossi, D ^a   Boscherini, B ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Bleomycin; Chromosome aberrations; DNA repair; GH; IGF I; IGF II; Radiosensitivity

Indexed keywords

BLEOMYCIN; GROWTH HORMONE; PROTEIN P53; SOMATOMEDIN B; SOMATOMEDIN C;

ARTICLE; CHROMOSOME ABERRATION; CHROMOSOME ANALYSIS; CHROMOSOME FRAGILITY; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE; TECHNIQUE;

BLEOMYCIN; CELLS, CULTURED; CHROMOSOME FRAGILITY; CYTOGENETICS; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; INSULIN-LIKE GROWTH FACTOR II; LYMPHOCYTES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0031881965     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1998.00247.x     Document Type: Article

References (35)

1. Guevara-Aguirre J, Vasconez O, Martinez V et al. A randomized, double-blind placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. Journal of Clinical Endocrinology and Metabolism, 1995; 80: 1393-1398.
2. Dunger DB. Insulin and insulin-like growth factors in diabetes mellitus. Archives of Diseases of Childhood, 1995; 72: 469-471.
3. Clemmons DR. Role of insulin-like growth factor-1 in reversing catabolism. Journal of Clinical Endocrinology and Metabolism, 1992; 75: 1183-1185.
4. Rosen CJ, Donahue LR. Insulin like growth factors: potential therapeutic options for osteoporosis. Trends in Endocrinology and Metabolism, 1995; 6: 235-241.
5. Clemmons DR, Underwood LE. Uses of human insulin-like growth factor-I in clinical conditions Journal of Clinical Endocrinology and Metabolism, 1994; 79: 4-6.
6. Hintz RL. Current and potential therapeutic uses of growth hormone and insulin-like growth factor I. Endocrinology and Metabolism Clinics of North America, 1996; 25: 759-773.
7. LeRoith D, Baserga R, Helman L, Roberts CT. Insulin-like growth factors and cancer. Annals of Internal Medicine, 1995; 122: 54-59.
8. Daughaday WH. The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology, 1990; 127: 1-4.
9. Macauley VM. Insulin-like growth factors and cancer. British Journal of Cancer, 1992; 5: 311-320.
10. Reeve JG, Kirby LB, Brinkman A, Hughes SA, Schwander J, Blechen M. Insulin-like growth factor-binding protein gene expression and protein production by human tumour cell lines. International Journal of Cancer, 1992; 51: 818-821.
11. Frost VJ, Mavauley VM, Wass JAH, Holly JMP. Proteolytic modification of insulin-like growth factor-binding proteins: comparison of conditioned media from human cell lines, circulating proteases and characterized enzymes. Journal of Endocrinology, 1993; 138: 545-554.
12. Cianfarani S, Rossi P. Neuroblastoma and insulin-like growth factor system. New insights and clinical perspectives. European Journal of Pediatrics, 1997; 156: 256-261.
13. Fisher DA, Job JC, Preece MA, Underwood LE. Leukemia in patients treated with growth hormone. Lancet, 1988; i: 1159-1160.
14. Tedeschi B, Spadoni GL, Sanna ML et al. Increased chromosome fragility in lymphocytes of short normal children treated with recombinant human growth hormone. Human Genetics, 1993; 91: 459-463.
15. Lane DP. p53guardian of the genome. Nature, 1992; 358: 15-16.
16. Jacks T, Weinberg RA. Cell-cycle control and its watchman. Nature, 1996; 381: 643-644.
17. Vojtesek B, Bartek J, Midgley CA, Lane DP. An immunochemical analysis of the human nuclear phosphoprotein p53. Journal of Immunological Methods, 1992; 151: 237-244.
18. Prokocimer M, Shaklai M, Bassat HB, Wolf D, Goldfinger N, Rotter V. Expression of p53 in human leukemia and lymphoma. Blood, 1986; 68: 113-118.
19. Wolf D, Rotter V. Major deletions in the gene encoding the p53 tumor antigen cause lack of p53 expression in HL-60 cells. Proceedings of the National Academy of Sciences of the USA, 1985; 82: 790-798.
20. Preston RJ, San Sebastian JR, McFee AF. The in vitro human lymphocytes assay for assessing the clastogenicity of chemical agents. Mutation Research, 1987; 189: 175-183.
21. MacLeod RAF, Voges M, Bryant PE, Drexler HG. Chromatid aberration dose responses and dispersal in human G2 lymphocytes treated with bleomycin: comparison with equivalent X-irradiation reveals formation of a novel class of heavily damaged cells. Mutation Research, 1994; 309: 73-81.
22. Kastan MB, Stone KD, Civin CI. Nuclear oncoprotein expression as a function of lineage, differentiation stage, and proliferative status of normal human hematopoietic cells. Blood, 1989; 74: 1517-1524.
23. Guyda HJ. Use of growth hormone in children with short stature and normal growth hormone secretion. Trends in Endocrinology and Metabolism, 1994; 5: 334-340.
24. Povirk LF, Finley Austin MJ. Genotoxicity of bleomycin. Mutation Research, 1991; 257: 127-143.
25. Spadoni GL, Spagnoli A, Cianfarani S et al. Enhancement by growth hormone of phorbol diester-stimulated respiratory burst in human polymorphonuclear leukocytes. Acta Endocrinologica, 1991; 124: 589-594.
26. Jayanth VR, Belfi CA, Swick AR, Varnes ME. Insulin and insulin-like growth factor-1 (IGF-1) inhibit repair of potentially lethal radiation damage and chromosome aberrations and alter DNA repair kinetics in plateau-phase A549 cells. Radiation Research, 1995; 143: 165-174.
27. Zhao X, McBride BW, Trouten-Radford LM, Burton JH. Effects of insulin-like growth factor-I and its analogues on bovine hydrogen peroxide release by neutrophils and blastogenesis by mononuclear cells. Journal of Endocrinology, 1993; 139: 259-265.
28. Bjerknes R, Aarskog D. Priming of human polymorphonuclear neutrophilic leukocytes by insulin-like growth factor-I. increased phagocytic capacity, complement receptor expression, degranulation, and oxidative burst. Journal of Clinical Endocrinology and Metabolism, 1995; 80: 1948-1955.
29. Phillips RA, Tolmach LJ. Repair of potentially lethal damage in x-irradiated HeLa Cells. Radiation Research, 1966; 29: 413-432.
30. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Research, 1991; 51: 6304-6311.
31. Chen WH, Pellegata NS, Wang PH. Coordinated effects of insulin-like growth factor-I on inhibitory pathways of cell cycle progression in cultured cardiac muscle cells. Endocrinology, 1995; 136: 5240-5243.
32. Beitner-Johnson D, LeRoith D. Insulin-like growth factor-I stimulates tyrosine phosphorylation of endogenous c-Crk. Journal of Biological Chemistry, 1995; 270: 5187-5190.
33. Zhang LJ, Kashanchi F, Zhan QM et al. Regulation of insulin-like growth factor-II P3 promoter by p53. A potential mechanism for tumorigenesis. Cancer Research, 1996; 56: 1367-1373.
34. Werner H, Karnieli E, Rauscher FJ, LeRoith D. Wild-type and mutant p53 differentially regulate trascription of the insulin-like growth factor-I receptor gene. Proceedings of the National Academy of Sciences of the USA, 1996; 93: 8318-8323.
35. Buckbinder L, Talbon R, Velasco-Miguel S et al. Induction of the growth inhibitor IGF-binding protein-3 by p53. Nature, 1995; 377: 646-649.